BioCentury
ARTICLE | Clinical News

CX-4945: Phase I started

September 27, 2010 7:00 AM UTC

Cylene began an open-label, dose-escalation, U.S. Phase I trial to evaluate oral CX-4945 given 4 times daily for the first 21 days of a 28-day cycle in 20 patients with relapsed or refractory MM. ...